Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...

Ten out of 11 children with a form of congenital deafness who were treated with an experimental gene therapy developed by ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...

In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...

As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearingSpeech and development ...

MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA," the "Company"), a clinical-stage biopharmaceutical company ...

Immune checkpoint inhibitors (ICPis) have revolutionized the therapeutic landscape of lung cancer with unprecedented survival results in most of the ...

MAIA Biotechnology (MAIA) announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in non-small cell lung cancer ...

Biotech stocks may be primed for a long-term bull run. Learn why IBB, XBI, and macro trends like rate cuts make biotech an ...

Regeneron Pharmaceuticals ... has demonstrated encouraging anti-tumour activity in patients with squamous non-small cell lung cancer (NSCLC). Meanwhile, its clinical pipeline also includes ...